New AI Blood Test Predicts Cancer Recurrence Months Early
Scientists from Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center, and Memorial Sloan Kettering Cancer Center have unveiled a cutting-edge AI-powered blood test that spots cancer returning with stunning accuracy.
Machine Learning Hunts Tumour DNA Across Multiple Cancers
The study, published in Nature Medicine on June 14, reveals a machine learning model trained to detect circulating tumour DNA (ctDNA). It’s proven effective for lung cancer, melanoma, breast cancer, colorectal cancer, and even precancerous colorectal polyps.
“We’ve achieved significant signal-to-noise enhancement, allowing us to detect cancer recurrence months or years before traditional methods,” said Dr Dan Landau of Weill Cornell Medicine.
MRD-EDGE: The AI That Outsmarts Traditional Testing
This breakthrough tech, called MRD-EDGE, uses whole-genome sequencing combined with AI to catch tiny cancer signals that often slip past standard liquid biopsy tests.
- Accurately predicts leftover cancer after surgery and chemotherapy in colorectal patients without false negatives.
- Works on early-stage lung and triple-negative breast cancers.
- Detects ctDNA even from precancerous colorectal adenomas.
A Game-Changer for Early Cancer Detection and Monitoring
Dr Landau highlighted the test’s potential to revolutionise cancer care by spotting recurrences early and monitoring tumour response during therapy. This could save countless lives by providing doctors with critical info much sooner than before.
